Head to Head Review: Neuphoria Therapeutics (NASDAQ:NEUP) vs. Ironwood Pharmaceuticals (NASDAQ:IRWD)

Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) and Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Profitability

This table compares Neuphoria Therapeutics and Ironwood Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neuphoria Therapeutics N/A -2.74% -2.31%
Ironwood Pharmaceuticals 37.38% -81.40% 42.69%

Institutional and Insider Ownership

15.9% of Neuphoria Therapeutics shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by company insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Neuphoria Therapeutics and Ironwood Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neuphoria Therapeutics 1 2 0 0 1.67
Ironwood Pharmaceuticals 0 4 2 1 2.57

Neuphoria Therapeutics currently has a consensus target price of $7.00, indicating a potential upside of 197.87%. Ironwood Pharmaceuticals has a consensus target price of $6.23, indicating a potential upside of 32.62%. Given Neuphoria Therapeutics’ higher probable upside, equities analysts clearly believe Neuphoria Therapeutics is more favorable than Ironwood Pharmaceuticals.

Volatility and Risk

Neuphoria Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500.

Earnings and Valuation

This table compares Neuphoria Therapeutics and Ironwood Pharmaceuticals”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neuphoria Therapeutics $1.17 million 10.87 -$13.45 million ($6.22) -0.38
Ironwood Pharmaceuticals $296.15 million 2.63 $24.02 million $0.90 5.22

Ironwood Pharmaceuticals has higher revenue and earnings than Neuphoria Therapeutics. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Ironwood Pharmaceuticals beats Neuphoria Therapeutics on 10 of the 15 factors compared between the two stocks.

About Neuphoria Therapeutics

(Get Free Report)

Neuphoria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing investigational treatments for neurological and psychiatric conditions. The company’s work centers on advancing drug candidates intended to address needs in brain health. Its products remain in development rather than being established, marketed therapies. Publicly available information about Neuphoria’s specific development programs, operating geographies and leadership is limited, so no additional details are included here.

About Ironwood Pharmaceuticals

(Get Free Report)

Ironwood Pharmaceuticals is a biotechnology company focused on developing and commercializing treatments for gastrointestinal diseases. Founded in 1998, the company is headquartered in Boston, Massachusetts. Its principal product is LINZESS (linaclotide), a prescription medicine for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. Ironwood and AbbVie collaborate on the product’s U.S. commercialization, while licensing partners make linaclotide available in other markets under regional brand names.

Receive News & Ratings for Neuphoria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.